[Efficacy of vaccine therapy with ribomunil in patients with chronic obstructive pulmonary disease].
OBJECTIVE
To assess efficacy of vaccine therapy with ribomunil in prevention of exacerbations and prolongation of remission in patients with obstructive pulmonary disease (COPD).


METHODS
Fifty three COPD patients were divided into two groups: 28 patients of the study group received ribomunil plus standard therapy; 25 controls received only standard treatment. The examination of the patients included blood count, sputum cytology, external respiration function test, immunological investigation (CD4+, CD8+, CD20+, CD25+ and CD95+; IL-4, IFN-gamma, complement). The examination was made before the treatment, 21 days, 3 and 6 months after its beginning. Ribomunil was given 3 tablets in the morning before meal for 4 days in a week for 3 weeks, 4 days each month for the following 5 months.


RESULTS
As a result of ribomunil treatment lymphocyte subpopulation normalized, immune response shifted to Th-1 dependent immune response, external respiration flow indices improved, remission prolonged.


CONCLUSIONS
Ribomunil is recommended for wide application in the practice of COPD treatment
Smirnova
Ia A
IaA
Trofimov
V I
VI
Shaporova
N L
NL
D000368:Aged; D000942:Antigens, Bacterial / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D016233:Immunotherapy, Active / Q000379:methods*; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D012074:Remission Induction; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D016896:Treatment Outcome
D000942:Antigens, Bacterial; D007155:Immunologic Factors; C034206:Ribomunyl